WP
KLRS

Woodline Partners’s Kalaris Therapeutics KLRS Stock Holding History

Woodline Partners’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$407K Hold
100,000
– – ﹤0.01% 981
2026
Q1 		$577K Hold
100,000
– – ﹤0.01% 944
2025
Q4 		$844K Sell
100,000
-141,102
-59% -$902K ﹤0.01% 852
2025
Q3 		$1.39M Buy
+241,102
New +$797K 0.01% 774
2025
Q2 		– Sell
-21,519
Closed -$173K – 1086
2025
Q1 		$173K Buy
21,519
+1,873
+10% +$18.3K ﹤0.01% 881
2024
Q4 		$190K Buy
+19,646
New +$297K ﹤0.01% 908
2024
Q1 		– Sell
-109,174
Closed -$1.71M – 655
2023
Q4 		$1.71M Buy
109,174
+19,319
+22% +$762K 0.02% 386
2023
Q3 		$4.44M Buy
89,855
+14,724
+20% +$1M 0.05% 327
2023
Q2 		$5.88M Buy
75,131
+31,653
+73% +$3.01M 0.07% 268
2023
Q1 		$3.94M Sell
43,478
-3,787
-8% -$482K 0.05% 324
2022
Q4 		$5.58M Hold
47,265
– – 0.07% 297
2022
Q3 		$8.58M Hold
47,265
– – 0.12% 217
2022
Q2 		$4.24M Hold
47,265
– – 0.07% 285
2022
Q1 		$7.34M Hold
47,265
– – 0.12% 206
2021
Q4 		$14.1M Sell
47,265
-16,194
-26% -$7.51M 0.2% 143
2021
Q3 		$36.6M Buy
63,459
+1,464
+2% +$678K 0.6% 38
2021
Q2 		$28.1M Buy
61,995
+10,694
+21% +$5.52M 0.52% 46
2021
Q1 		$27.6M Buy
51,301
+6,089
+13% +$5.12M 0.61% 50
2020
Q4 		$40M Sell
45,212
-6,571
-13% -$5.06M 1.06% 25
2020
Q3 		$32.8M Buy
+51,783
New +$35.4M 1.07% 28

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Woodline Partners's KLRS Position: Q2 2026 in Review

Woodline Partners held its Kalaris Therapeutics (KLRS) position steady in Q2 2026 at 100,000 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #981.

Woodline Partners first reported a position in KLRS in Q3 2020 and has held it in 20 quarters since. The position peaked at $40M in Q4 2020. 56 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Woodline Partners held 100,000 shares of Kalaris Therapeutics worth $407K as of Q2 2026.
  • Woodline Partners left its Kalaris Therapeutics share count unchanged in Q2 2026.
  • Kalaris Therapeutics made up ﹤0.01% of Woodline Partners's portfolio in Q2 2026, its #981 holding.
  • Woodline Partners first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 20 quarters since.
  • Woodline Partners's Kalaris Therapeutics position peaked at $40M in Q4 2020.
  • 56 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.